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Abstract
Background: The association between maternal serum concentration of betamethasone given for fetal lung maturity
and perinatal outcome has not been investigated. This may be due to an absence of a reliable method for measuring
serum betamethasone concentrations. We aimed in the current study to assess the feasibility of a specific ELISA kit to
measure the concentrations of betamethasone in maternal serum and to examine the trend of sequential
measurements after a course of betamethasone for fetal lung maturity.
Methods: Pregnant women at risk for preterm birth who received betamethasone between 24 and 34 weeks of
gestation were prospectively included. Serum concentrations were determined before administering betamethasone
(baseline), and 36 hours, 48 hours, 72 hours, and 5 to 7 days after the 1st dose. Betamethasone concentration in
samples was determined using Corticosteroid ELISA kit. The Friedman test was used to test whether there were
significant differences between the measurements.
Results: Five singleton pregnancies were included. Using the ELISA kit, betamethasone concentration in maternal
serum samples was obtained for all women. Among the five measurements performed, the concentration was highest
at 36 hours after the 1st dose and close to baseline at the 5th measurement performed after 5 to 7 days (p < 0.05).
Serum concentration varied at each time point between the five women but similar trend was observed.
Conclusion: Betamethasone concentration is measurable in the serum of pregnant women with this ELISA kit.
Keywords: Betamethasone concentration, ELISA kit, Preterm birth, Respiratory distress syndrome
Background
Preterm birth is a major contributor to perinatal mortality
and morbidity and affects approximately 7 to 12% of births
in developed countries [1]. It is responsible for approxi-
mately 75% of all neonatal deaths and 50% of childhood
neurological morbidities. Additionally, these premature
infants are at high risk for acute medical complications in-
cluding respiratory distress syndrome, intraventricular
hemorrhage, and necrotizing enterocolitis [2, 3].
Liggins’ 1969 study with sheep that found improved sur-
vival for preterm lambs delivered after corticosteroid ex-
posure [4], paved the way for one of the most important
developments in antenatal care for women at risk for
preterm birth [5]. Subsequent randomized controlled tri-
als, which demonstrated reduced perinatal mortality and
morbidity, particularly respiratory distress syndrome, led
to a change in antenatal care, and antenatal betametha-
sone therapy has become a standard of care in the major-
ity of medical centers worldwide [6, 7].
The currently accepted dosage of betamethasone was
determined by Liggins and Howie in the 1970s; since that
time, pregnant women at risk for preterm birth have been
administered a fixed dosage of betamethasone, regardless
of gestational age, maternal body mass index, and the
presence of a singleton or multiple gestation [8]. Although
betamethasone treatment reduces mortality and morbidity
in general [9], its effect for a particular woman may be
unpredictable, and varying outcomes between two pre-
term neonates with similar obstetrical background
born at a similar gestational age after treatment with
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betamethasone may often be observed. Moreover,
among multiple pregnancies, the benefit of betametha-
sone is uncertain [10, 11]. For that reason the optimal
dosage for betamethasone in terms of benefit and
safety is still unknown.
To the best of our knowledge, the relationship between
betamethasone concentration and perinatal outcome has
not been reported. In part, this may be due to an absence
of a reliable method for measuring serum betamethasone
concentrations. In view of that, we aimed in this study to
assess the ability of a specific ELISA kit to measure the
concentrations of betamethasone in maternal serum and
to examine the trend of sequential measurements in ma-
ternal serum after a complete course of betamethasone
for lung maturity.
Methods
This prospective study was held at a university teaching
medical center between July 2012 and April 2014. Preg-
nant women between 24 weeks 0 days and 33 weeks 6
days of gestation, had singleton gestation, and received a
complete course of betamethasone due to threatened
preterm birth were included. A complete course of beta-
methasone (consisting of 50% betamethasone phosphate
and 50% betamethasone acetate) involved two 12 mg
intramuscular doses 24 hours apart. Women who re-
ceived an incomplete course of betamethasone because
of failure to delay delivery or who received corticoste-
roids for other reasons during pregnancy, had multiple
gestations, or fetal malformations diagnosed in the ante-
partum period were excluded from the study.
In order to examine whether betamethasone levels are
measurable and in order to examine the dynamics of
betamethasone concentrations against time from treat-
ment, blood samples were drawn from each participating
woman at five time points: immediately before adminis-
tering the betamethasone (baseline); at 36 hours after
the first dose; at 48 hours after the first dose; at 72 hours
after the first dose, and 5 to 7 days after the first dose,
given that a preterm birth did not occur earlier. These
consecutive measurements were chosen in order to
examine whether the trend of concentrations acted com-
parably to the anticipated clinical effect of betametha-
sone, which is best achieved within 7 days from the
initial dose [9].
In order to examine whether half-life (t1/2) of beta-
methasone concentration varies during different periods
after betamethasone administration and between the par-
ticipating women, t1/2 of betamethasone was calculated
between the second and third measurements (36 to 48
hours after the first injection) and between the third and
fourth measurements (48 to 72 hours after the first injec-
tion) for all women. Calculation was performed using the
formula t1/2 = t * ln(2)/ln(N0/Nt) where, t = time between
measurements, ln = natural logarithm, N0 = concentration
at the beginning, and Nt = concentration at the end of the
time between the two measurements.
Determining betamethasone concentrations
Serum samples were kept at -70°C until processing. Beta-
methasone concentration in samples was determined
using the Corticosteroid ELISA kit (Randox Laboratories
Ltd., Crumlin, BT29, UK) according to the manufacturer’s
instructions, processed in a Triturus apparatus (Grifols
Diagnostics, Parets del Valles, Spain). This kit, originally
designed for urine, tissue, and serum samples in the veter-
inary field, was evaluated in our laboratory for use with
human samples. Evaluation included precision, repeatabil-
ity, linearity, and analytical sensitivity (lower limit of de-
tection). Those parameters were analyzed by spiking
betamethasone (provided with the kit) and the same gen-
eric betamethasone that was administered to women into
a pool of human sera. According to linearity range ob-
tained in the evaluation, study samples were diluted ac-
cordingly in order to be measured within this range.
The present study was approved by the ethics commit-
tee of Emek Medical Center in compliance with the
Helsinki declaration. Signed consent was obtained from
each of the participating women before receiving the
first betamethasone injection.
Statistical analysis
The mean and standard deviation of the betamethasone
levels from all samples were calculated. The Friedman
test was used to determine whether there were signifi-
cant differences between betamethasone concentrations.
Significance level was set at p < 0.05. For continuous var-
iables, the Student t-test was implemented. SAS 9.2 was
used to perform the statistical analyses and the graphical
presentation (SAS Institute Inc., Cary, NC, USA).
Results
A total of eight women were approached and consented.
Three women delivered before receiving a complete course
of betamethasone and for that reason they were excluded.
Overall, five women (A to E) received a complete course of
betamethasone and were included in the study. Demo-
graphic and obstetric parameters are presented in Table 1.
Base line and last measurements of woman E were not per-
formed; the first was due to technical issues and the last
due to the fact that she delivered before the scheduled
examination. Among all women, two delivered preterm,
woman B and woman E (Table 1). Woman B delivered at
30 weeks of gestation, 3 weeks after betamethasone admin-
istration. Betamethasone concentration 48 hours after the
first dose was 0.64 ng/mL. The neonate developed respira-
tory distress syndrome. Woman E delivered at 29 weeks
of gestation, less than a week after betamethasone
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administration. Betamethasone concentration 48 hours
after the first dose was 1.61 ng/mL. The neonate did not
develop respiratory distress syndrome. The other 3
women delivered at term. None of the neonates developed
intraventricular hemorrhage or necrotizing enterocolitis.
As shown in Fig. 1, betamethasone concentrations could
be measured in the human serum samples. Among the
measurements performed for each woman, the concentra-
tion was highest 36 hours after the first dose of betametha-
sone. The concentration diminished gradually to a level
close to the baseline at the 5th measurement performed 5
to 7 days after the first dose of betamethasone. The trend
between measurements was significant (p < 0.05). Al-
though the trend of sequential measurements was similar
for the five women, there were obvious variations at each
time point (Fig. 1).
Calculated half-life of betamethasone differed accord-
ing to the time elapsed from its administration
(Table 2). Mean half-life after 36 to 48 hours from
administration (21.2 ± 10.6 hours) was significantly
shorter compared to 48 to 72 hours after administra-
tion (82 ± 35.6 hours), (p = 0.006).
The evaluation of betamethasone measurement kit
performance demonstrated a high precision for spiked
betamethasone in the human sera pool: average coeffi-
cient of variation of 3.5 and 6.1% for kit and generic
betamethasone, respectively, for expected values be-
tween 0.1 and 50 ng/mL. The kit demonstrated a good
linearity (average bias = ±4.0%) for the range between 0.1
and 50 ng/mL. Analytical sensitivity (lower limit of de-
tection) was 0.05 ng/mL.
Discussion
In this study we were able to measure betamethasone con-
centrations in the serum of pregnant women with the use
of corticosteroid ELISA kit. Among the measurements
performed for each woman, the concentration was highest
at 36 hours after the first dose of betamethasone followed














A 25 29.8 1 27.6 Preterm labor 37.1 No
B 25 27.5 0 27 Preterm labor 30.0 Yes
C 27 33.1 1 32.2 Preeclampsia 37.4 No
D 36 29.7 2 32.1 Preeclampsia 39.3 No
E 33 26.4 0 28.2 Preterm labor 29.0 No
aCalculated at the time of betamethasone treatment
Fig. 1 Trends of the sequential betamethasone concentration measurements of the 5 women included in the study
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by a gradual decrease to a level close to the baseline at the
5th measurement at 5 to 7 days. The trend of sequential
measurements performed similarly between all women;
however the concentration varied at each time point be-
tween the five women. The near to baseline concentration
at 5 to 7 days is similar to the described perinatal clinical
effect that is best achieved within 7 days after drug admin-
istration [9].
The National Institutes of Health and the American
College of Obstetricians and Gynecologists recommend
routine glucocorticoid administration to women at risk
for preterm birth between 24 and 34 weeks gestation to
accelerate fetal lung maturation and to decrease the inci-
dence of other neonatal morbidity and mortality related
to prematurity [7, 12]. When betamethasone is adminis-
tered, the recommended regimen is two doses, 12 mg
each, given intramuscularly 24 hours apart [7, 12].
Although betamethasone treatment reduces mortality
and morbidity in general, its effect on a particular woman
is usually unpredictable. The current dosage of beta-
methasone was determined by Liggins and Howie during
the 1970s, and since then a fixed dosage is administered
to all pregnant women regardless of gestational age, ma-
ternal body mass index, and whether a singleton or mul-
tiple gestation is present [8]. Additionally, betamethasone
rapidly crosses the placenta [13]. Its administration to the
pregnant mother inevitably exposes the fetus to gluco-
corticoid concentrations that may be inappropriate for the
current stage of fetal development [14]. High blood pres-
sure [15], reduced head circumference at birth [16], and
reduced brain weight in monkey fetuses [17, 18] are
among the several adverse effects reported after gluco-
corticoid given to enhance fetal lung maturity. In view of
that, the optimum betamethasone dosage and concentra-
tion in terms of benefit and safety to the developing fetus
at any gestational age has not been established.
Loehle et al. reported that routine therapy of two 12 mg
doses of betamethasone phosphate alone given intramus-
cularly to the average weight mother 24 h apart is supra-
maximal for fetal lung maturation. Their data showed that
half the normal clinical dose, adjusted for weight, may be
functionally adequate [14]. On the other hand, Ballabh et
al. reported that the efficacy of betamethasone to promote
fetal lung maturation in twin pregnancy may be reduced
since the dose of betamethasone is suboptimal [19]. They
reported that the reasons are due to shorter half-life and
greater clearance of betamethasone in twin pregnancy
than in singleton pregnancy. This may be attributed to the
presence of two fetoplacental units in twins, which causes
greater metabolism of betamethasone than in singletons
[19], or a dilution effect due to the increased maternal
blood volume and total body water [20]. In contrast to the
previous studies we show that there is a variation in the
concentrations among women with singleton pregnancies
and a fixed dosage, whether smaller or larger than the ac-
ceptable regimen, may not be sufficient to reduce perinatal
complications among all women.
The half-lives of betamethasone concentration found in
the current study differ from the fixed 9.0 ± 2.7 hours re-
ported by Ballabh et al. [19]. This may be due to impreci-
sion in the technique used to measure betamethasone
concentrations. Ballabh et al. used a radioimmunoassay
that was originally developed to measure dexamethasone
and was modified to measure betamethasone concentra-
tion [19]. Additionally, and compared to their results, two
different half-lives were noted in the current study. Sahin
et al. reported that for most drugs there is no single half-
life that can be readily accepted. This is due to the fact
that the systemic concentration time profile for most
drugs is best described by a multi-exponential function,
thereby yielding more than one half-life to describe the
drug. The choice of a single appropriate half-life value for
such drugs is unclear [21]. This may also be explained
with the two-compartment model that adds a peripheral
compartment to the one-compartment model. The per-
ipheral compartment represents the opportunity for a
drug to leave the plasma and enter other tissues. Among
pregnant women, a third compartment may be present –
the fetoplacental. Drugs transfer to the fetus across the
placenta and elimination from the fetus is by diffusion
back to the maternal compartment. Moreover, the fetus
plays an important role in the equilibrium of a compound
because the fetus swallows amniotic fluid and urinates;
there is a sort of drug recirculation within the fetal com-
partment along with the transfer back to maternal blood
[22]. This may explain the existence of more than one
half-life found in the current study.
Conclusions
The results of the current study do not provide evidence
as to the precise dosage of betamethasone that needs to
be administered; the minimum betamethasone dosage
that would be clinically effective is yet to be determined.
Basic pharmacologic principles suggest that the drug
concentration in maternal serum may determine the
fetal response and perinatal outcome and, as such, the
Table 2 Calculated half-life of betamethasone concentrations among the participating women
Woman A Woman B Woman C Woman D Woman E Mean±SD
T1/2, 36–48 hours after 1
st dose (hours) 9.0 22.9 28.5 12.0 33.7 21.2 ± 10.6
T1/2, 48–72 hours after 1
st dose (hours) 72.7 88.2 57.0 51.8 140.3 82 ± 35.6
Data are mean ± standard deviation. T1/2, Half-life
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optimal treatment regimen. Given that, the results of the
current study may pave the way for future studies that
could determine the optimum concentration and, ac-
cordingly, the dosage of betamethasone by investigating
the minimum concentration that would be clinically ef-
fective to positively affect perinatal outcome.
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